Investors Buy High Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Stock investors acquired 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Maravai LifeSciences Trading Up 1.1%

NASDAQ MRVI opened at $3.73 on Thursday. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $953.80 million, a P/E ratio of -4.44 and a beta of 0.33. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $6.21. The firm has a 50-day moving average price of $3.36 and a 200 day moving average price of $2.78.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $41.63 million during the quarter, compared to analysts’ expectations of $49.02 million. Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. Equities research analysts expect that Maravai LifeSciences will post -0.24 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.36.

Insiders Place Their Bets

In other Maravai LifeSciences news, Director Gregory T. Lucier bought 48,528 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was acquired at an average price of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the purchase, the director owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. This represents a 45.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernd Brust purchased 216,212 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average cost of $3.25 per share, for a total transaction of $702,689.00. Following the acquisition, the chief executive officer owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. The trade was a 86.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 566,771 shares of company stock valued at $1,880,244. 2.11% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. 12 West Capital Management LP lifted its holdings in Maravai LifeSciences by 8.0% in the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock valued at $27,672,000 after acquiring an additional 930,000 shares during the period. Mirabella Financial Services LLP grew its stake in shares of Maravai LifeSciences by 0.3% during the 2nd quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company’s stock worth $9,038,000 after purchasing an additional 10,049 shares during the period. Monaco Asset Management SAM increased its holdings in shares of Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 12.0% in the second quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company’s stock valued at $7,193,000 after purchasing an additional 319,679 shares during the period. Finally, Philosophy Capital Management LLC purchased a new stake in Maravai LifeSciences during the first quarter worth about $5,731,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.